January 30, 2026
Clinical Updates
Nexplanon® (etonogestrel) – Expanded indication
January 16, 2026 - Organon announced the FDA approval of Nexplanon (etonogestrel), for prevention of pregnancy in women of reproductive potential for up to 5 years.
Drug Approvals
Filkri® (filgrastim-laha) – New biosimilar approval
January 15, 2026 - The FDA approved Accord Biopharma’s Filkri (filgrastim-laha), biosimilar to Amgen’s Neupogen® (filgrastim).
Drug Recalls - Availability
Integra Lifesciences – Recall of MediHoney® wound and burn products
January 16, 2026 - Integra Lifesciences announced a voluntary, consumer-level recall of all unexpired lots of MediHoney wound and burn products because packaging failures were identified which could lead to a breach in the sterile barrier.
Drug Recalls - Availability
ViiV Healthcare Company – Discontinuation of Selzentry® (maraviroc) 20 mg/mL oral solution kit
January 20, 2026 - ViiV Healthcare Company announced a business decision to discontinue Selzentry (maraviroc) 20 mg/mL oral solution kit. Selzentry is not being discontinued for reasons of safety or effectiveness.
Drug Recalls - Availability
Glaukos Corporation – Discontinuation of Photrexa® (riboflavin 5-phosphate) cross-linking kit
January 20, 2026 - Glaukos Corporation announced a business decision to discontinue Photrexa (riboflavin 5-phosphate) cross-linking kit, ophthalmic solution. Photrexa is not being discontinued for reasons of safety or effectiveness.